Company: ABBV
Filing Date: 2025-02-20
Form Type: 424B5
Source: 0001104659-25-015715
Chunk: 69

Company: AbbVie Inc.
Filing Date: 2025-02-20
Form: 424B5
Chunk 69
---
Vie to Abbott’s shareholders.

AbbVie also maintains an Internet site at www.abbvie.com. AbbVie’s website and the information contained therein or connected thereto shall not be deemed to be incorporated herein, and you should not rely on any such information in making an investment decision.

The address of AbbVie’s principal executive offices is 1 North Waukegan Road, North Chicago, Illinois 60064-6400. AbbVie’s telephone number is (847) 932-7900.

<div align='center'>3</div>

TABLE OF CONTENTS

### INFORMATION INCORPORATED BY REFERENCE
The SEC allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will automatically update and supersede information included or previously incorporated by reference into this prospectus from the date we file the document containing such information. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Except to the extent furnished and not filed with the SEC pursuant to Item 2.02 or 7.01 of Form 8-K or as otherwise permitted by the SEC rules, we incorporate by reference the documents listed below and any future filings we will make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), from the date of this prospectus until the completion of the offering in the relevant prospectus supplement to which this prospectus relates or the offering is terminated.

The documents we incorporate by reference into this prospectus are:

1.

Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 14, 2025;

2.

The information in Part III of the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 20, 2024,incorporated by reference from the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on March 18, 2024; and

3.

The Company’s Current Reports on Form 8-K as filed with the SEC on